<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023581</url>
  </required_header>
  <id_info>
    <org_study_id>SYR-322MET_302</org_study_id>
    <secondary_id>2009-012652-24</secondary_id>
    <secondary_id>U1111-1112-1912</secondary_id>
    <secondary_id>DOH-27-0910-3155</secondary_id>
    <secondary_id>CTRI/2010/091/000253</secondary_id>
    <nct_id>NCT01023581</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes</brief_title>
  <acronym>AM7D</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of alogliptin combined
      with metformin, once daily (QD) or twice daily (BID), in participants with Type 2 Diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are approximately 19 million people in the United States who have been diagnosed with
      diabetes mellitus, of which 90% to 95% are type 2. The prevalence of type 2 diabetes varies
      among racial and ethnic populations and has been shown to correlate with age, obesity, family
      history, history of gestational diabetes and physical inactivity. Over the next decade, a
      marked increase in the number of adults with diabetes mellitus is expected.

      Metformin is the usual choice of first-line therapy for type 2 diabetes. Metformin targets
      insulin resistance in type 2 diabetes by inhibiting hepatic glucose production and
      stimulating glucose uptake in skeletal muscle and adipose tissue, which results in a
      long-term glucose-lowering effect.

      Alogliptin is an inhibitor of the dipeptidyl peptidase IV enzyme. Dipeptidyl peptidase-4
      enzyme is thought to be primarily responsible for the in vivo degradation of 2 peptide
      hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and
      glucose-dependent insulinotropic peptide. Both peptides exert important effects on islet beta
      cells to stimulate glucose-dependent insulin secretion as well as regulating beta cell
      proliferation and cytoprotection. Glucagon-like peptide-1, but not glucose-dependent
      insulinotropic peptide, inhibits gastric emptying, glucagon secretion, and food intake.
      Glucose-dependent insulinotropic peptide has been shown to enhance insulin secretion by
      direct interaction with a glucose-dependent insulinotropic peptide -specific receptor on
      islet beta cells. The glucose-lowering actions of glucagon-like peptide-1, but not
      glucose-dependent insulinotropic peptide, are preserved in patients with type 2 diabetes
      mellitus. It is expected that inhibition of dipeptidyl peptidase IV will improve glycemic
      (glucose) control in patients with type 2 diabetes.

      Based on the potential, complimentary mechanisms of action of alogliptin and metformin, this
      study will compare the safety and efficacy of alogliptin and metformin (SYR-322MET) on
      improving glycemic control in patients with type 2 diabetes mellitus who are inadequately
      controlled by diet adjustment and exercise alone.

      Participants taking part in this study will receive dietary and exercise coaching, and will
      monitor their own blood glucose concentrations with a home glucose monitor. Participants will
      also be required to maintain a hypoglycemic diary throughout the course of the study.
      Participation in this study is expected to last up to 34 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26</measure>
    <time_frame>Baseline and Week 26.</time_frame>
    <description>The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c Over Time</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, and 20.</time_frame>
    <description>The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was assessed at Weeks 4, 8, 12, 16 and 20.
Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as fixed effects, and baseline HbA1c as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose Over Time</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.</time_frame>
    <description>The change from Baseline in fasting plasma glucose was assessed at Weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as fixed effects, and baseline fasting plasma glucose as a covariate.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">784</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alogliptin 25 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alogliptin 12.5 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin 500 BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin 1000 BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alogliptin 12.5 BID + Metformin 500 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alogliptin 12.5 BID + Metformin 1000 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin</intervention_name>
    <description>Alogliptin tablets.</description>
    <arm_group_label>Alogliptin 25 QD</arm_group_label>
    <arm_group_label>Alogliptin 12.5 BID</arm_group_label>
    <arm_group_label>Alogliptin 12.5 BID + Metformin 500 BID</arm_group_label>
    <arm_group_label>Alogliptin 12.5 BID + Metformin 1000 BID</arm_group_label>
    <other_name>SYR-322</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin capsules</description>
    <arm_group_label>Metformin 500 BID</arm_group_label>
    <arm_group_label>Metformin 1000 BID</arm_group_label>
    <arm_group_label>Alogliptin 12.5 BID + Metformin 500 BID</arm_group_label>
    <arm_group_label>Alogliptin 12.5 BID + Metformin 1000 BID</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Glucophage XR</other_name>
    <other_name>Riomet</other_name>
    <other_name>Fortamet</other_name>
    <other_name>Glumetza</other_name>
    <other_name>Obimet</other_name>
    <other_name>Dianben</other_name>
    <other_name>Diabex</other_name>
    <other_name>Diaformin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin Placebo</intervention_name>
    <description>Alogliptin placebo-matching tablets.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Metformin 500 BID</arm_group_label>
    <arm_group_label>Metformin 1000 BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Placebo</intervention_name>
    <description>Metformin placebo-matching capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Alogliptin 25 QD</arm_group_label>
    <arm_group_label>Alogliptin 12.5 BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has historical diagnosis of Type 2 Diabetes Mellitus.

          -  Has been treated with diet and exercise for at least 2 months prior to Screening, and
             has a Glycosylated Hemoglobin concentration between 7.5% and 10.0%, inclusive at
             Screening.

          -  Has received less than 7 days of any antidiabetic medication within 2 months prior to
             Screening.

          -  Body mass index greater than or equal to 23 kg/m^2 and less than or equal to 45 kg/m^2
             (except for Asian or Asian-descendant subjects for whom the range is between 20 and 35
             kg/ m^2, inclusive).

          -  Fasting C-peptide concentration greater than or equal to 0.8 ng/mL.

          -  Regularly using other, non-excluded, medications must be on a stable dose for at least
             the 4 weeks prior to Screening.

          -  Females of childbearing potential and males who are sexually active agree to routinely
             use adequate contraception from Screening throughout the duration of the study.

          -  Able and willing to monitor their own blood glucose concentrations with a home glucose
             monitor and complete patient diaries.

        Exclusion Criteria:

          -  Hemoglobin less than 12 g/dL for males and less than 10 g/dL for females at Screening
             Visit.

          -  Has a history of any hemoglobinopathy that may affect determination of Glycosylated
             Hemoglobin.

          -  Has a history of laser treatment for proliferative diabetic retinopathy within the 6
             months prior to Screening.

          -  Has a history of treatment for diabetic gastric paresis, gastric banding, or gastric
             bypass surgery.

          -  Has a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma.

          -  Has systolic blood pressure greater than or equal to 150 mmHg and /or diastolic
             pressure greater than or equal to 90 mmHg at Screening visit.

          -  Has New York Heart Association Class III to IV heart failure.

          -  Has a history of coronary angioplasty, coronary stent placement, coronary bypass
             surgery, or myocardial infarction within the 90 days prior to Screening.

          -  Has Alanine aminotransferase greater than 3 times the upper limit of normal at
             Screening.

          -  Has a history of alcohol or substance abuse with the 2 years prior to Screening.

          -  Serum creatinine greater than or equal to 1.5 mg/dL for males and greater than or
             equal to 1.4 mg/dL for females.

          -  Has history of cancer, other than squamous cell or basal cell carcinoma of the skin
             that has not been in full remission for at least 5 years prior to Screening.

          -  Has a history of infection with human immunodeficiency virus, hepatitis B virus or
             hepatitis C virus.

          -  Has any major illness or debility that in the investigator's opinion prohibits the
             subject from completing the study.

          -  Has received any investigational drug within the 90 days prior to Screening.

          -  Has a history of hypersensitivity or allergy to alogliptin, other DPP-4 inhibitors,
             metformin or related compounds.

          -  Has used oral or systematically injected glucocorticoids or weight loss drugs prior to
             2 months to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vice President, Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pell City</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sierra Vista</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Searcy</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cathedral City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cutler Bay</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Opa Locka</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hayden Lake</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melrose Park</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Porte</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Picayune</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Massapequa</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gallipolis</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maumee</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bensalem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Downingtown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fleetwood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perkasie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shippensburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tipton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murrells Inlet</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Myrtle Beach</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taylors</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brentwood</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crossville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McKenzie</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spring Hill</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deer Park</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schertz</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spring</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sugarland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petersburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 10</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Znojmo</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budaors</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyongyos</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Komarom</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Safed</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kedainiai</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Acapulco, Guerrero</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cuernavaca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Culiacan, Sinoloa</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Distrito Federal</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durango, Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City, Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico, DF</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monclova, Coahuila</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey, NL</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pachuca, Hidalgo</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pachuca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saltillo</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tijuana, Baja California</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zapopan, Jalisco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bytom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gniewkowo</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kamieniec Zabkowicki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leczyca</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caguas</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cidra</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salinas</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santurce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trujilo Alto</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bacau</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baia Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ploiesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irkutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perm</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prievidza</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sahy</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Centurion</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <state>Kwazulu-Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Chile</country>
    <country>Guatemala</country>
    <country>India</country>
    <country>Peru</country>
  </removed_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <results_first_submitted>February 17, 2013</results_first_submitted>
  <results_first_submitted_qc>February 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2013</results_first_posted>
  <last_update_submitted>February 17, 2013</last_update_submitted>
  <last_update_submitted_qc>February 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes mellitus</keyword>
  <keyword>Non-insulin dependent diabetes mellitus</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Hypoglycemia,</keyword>
  <keyword>Hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alogliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 198 investigative sites worldwide from 16 November 2009 to 30 June 2011.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of type 2 diabetes and glycemia inadequately controlled on diet and exercise alone were randomly assigned with equal probability to 1 of 7 treatment groups, including placebo, alogliptin alone, metformin alone or a combination of alogliptin and metformin.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Alogliptin 25 QD</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Alogliptin 12.5 BID</title>
          <description>Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Metformin 500 BID</title>
          <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Metformin 1000 BID</title>
          <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Alogliptin 12.5 BID + Metformin 500 BID</title>
          <description>Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Alogliptin 12.5 BID + Metformin 1000 BID</title>
          <description>Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="113"/>
                <participants group_id="P4" count="114"/>
                <participants group_id="P5" count="111"/>
                <participants group_id="P6" count="111"/>
                <participants group_id="P7" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="110"/>
                <participants group_id="P4" count="109"/>
                <participants group_id="P5" count="111"/>
                <participants group_id="P6" count="106"/>
                <participants group_id="P7" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74">The number of completed patients represents those who completed study drug.</participants>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="94"/>
                <participants group_id="P5" count="95"/>
                <participants group_id="P6" count="92"/>
                <participants group_id="P7" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Major protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Alogliptin 25 QD</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Alogliptin 12.5 BID</title>
          <description>Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Metformin 500 BID</title>
          <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Metformin 1000 BID</title>
          <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Alogliptin 12.5 BID + Metformin 500 BID</title>
          <description>Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Alogliptin 12.5 BID + Metformin 1000 BID</title>
          <description>Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
            <count group_id="B2" value="112"/>
            <count group_id="B3" value="113"/>
            <count group_id="B4" value="114"/>
            <count group_id="B5" value="111"/>
            <count group_id="B6" value="111"/>
            <count group_id="B7" value="114"/>
            <count group_id="B8" value="784"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.1" spread="9.60"/>
                    <measurement group_id="B2" value="52.6" spread="9.38"/>
                    <measurement group_id="B3" value="53.7" spread="9.70"/>
                    <measurement group_id="B4" value="54.6" spread="10.20"/>
                    <measurement group_id="B5" value="52.6" spread="11.30"/>
                    <measurement group_id="B6" value="53.7" spread="11.59"/>
                    <measurement group_id="B7" value="54.6" spread="10.42"/>
                    <measurement group_id="B8" value="53.5" spread="10.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="95"/>
                    <measurement group_id="B5" value="94"/>
                    <measurement group_id="B6" value="91"/>
                    <measurement group_id="B7" value="96"/>
                    <measurement group_id="B8" value="675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="60"/>
                    <measurement group_id="B6" value="63"/>
                    <measurement group_id="B7" value="52"/>
                    <measurement group_id="B8" value="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="48"/>
                    <measurement group_id="B7" value="62"/>
                    <measurement group_id="B8" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="45"/>
                    <measurement group_id="B7" value="39"/>
                    <measurement group_id="B8" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="69"/>
                    <measurement group_id="B6" value="66"/>
                    <measurement group_id="B7" value="75"/>
                    <measurement group_id="B8" value="482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="26"/>
                    <measurement group_id="B8" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="85"/>
                    <measurement group_id="B5" value="79"/>
                    <measurement group_id="B6" value="76"/>
                    <measurement group_id="B7" value="78"/>
                    <measurement group_id="B8" value="561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.15" spread="5.269"/>
                    <measurement group_id="B2" value="30.81" spread="5.219"/>
                    <measurement group_id="B3" value="30.36" spread="5.159"/>
                    <measurement group_id="B4" value="30.19" spread="4.842"/>
                    <measurement group_id="B5" value="30.51" spread="5.043"/>
                    <measurement group_id="B6" value="30.92" spread="5.353"/>
                    <measurement group_id="B7" value="31.04" spread="5.375"/>
                    <measurement group_id="B8" value="30.71" spread="5.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.25" spread="4.778"/>
                    <measurement group_id="B2" value="3.65" spread="4.119"/>
                    <measurement group_id="B3" value="3.97" spread="4.800"/>
                    <measurement group_id="B4" value="3.78" spread="3.904"/>
                    <measurement group_id="B5" value="4.08" spread="4.587"/>
                    <measurement group_id="B6" value="4.13" spread="4.777"/>
                    <measurement group_id="B7" value="4.22" spread="4.972"/>
                    <measurement group_id="B8" value="4.01" spread="4.563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline HbA1c</title>
          <description>The count for baseline HbA1c category is based on HbA1c value used in randomization for stratification.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>8.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="66"/>
                    <measurement group_id="B6" value="66"/>
                    <measurement group_id="B7" value="67"/>
                    <measurement group_id="B8" value="465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;8.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="45"/>
                    <measurement group_id="B7" value="47"/>
                    <measurement group_id="B8" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26</title>
        <description>The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).</description>
        <time_frame>Baseline and Week 26.</time_frame>
        <population>Full analysis set (patients who took at least 1 dose of study medication) where baseline and at least 1 postbaseline assessment were available. Analysis includes only data collected on or after baseline and within 7 days after last dose of study medication or hyperglycemic rescue, whichever came first. Last observation carried forward was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Metformin 500 BID</title>
            <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Metformin 1000 BID</title>
            <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Alogliptin 12.5 BID + Metformin 500 BID</title>
            <description>Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Alogliptin 12.5 BID + Metformin 1000 BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26</title>
          <description>The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).</description>
          <population>Full analysis set (patients who took at least 1 dose of study medication) where baseline and at least 1 postbaseline assessment were available. Analysis includes only data collected on or after baseline and within 7 days after last dose of study medication or hyperglycemic rescue, whichever came first. Last observation carried forward was utilized.</population>
          <units>percentage glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="108"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.094"/>
                    <measurement group_id="O2" value="-0.52" spread="0.094"/>
                    <measurement group_id="O3" value="-0.56" spread="0.093"/>
                    <measurement group_id="O4" value="-0.65" spread="0.094"/>
                    <measurement group_id="O5" value="-1.11" spread="0.092"/>
                    <measurement group_id="O6" value="-1.22" spread="0.094"/>
                    <measurement group_id="O7" value="-1.55" spread="0.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy analysis consisted of 2 separate sets of comparisons between each BID combination of alogliptin and metformin (alogliptin/metformin 12.5/500 mg BID and 12.5/1000 mg BID) and its constituent doses of alogliptin and metformin. The null hypothesis was that the combination of alogliptin and metformin had no additional effect on glycemic control at Week 26 either when compared with the constituent dose of alogliptin or with the constituent dose of metformin.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>For each set of comparisons in the primary analysis, the null hypothesis was rejected only if both comparisons between a combination and its constituent doses were statistically significant at the 2-sided 2.5% level.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment and geographic region as fixed effects and baseline HbA1c as a covariate.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.96</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment and geographic region as fixed effects and baseline HbA1c as a covariate</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment and geographic region as fixed effects and baseline HbA1c as a covariate.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.29</ci_lower_limit>
            <ci_upper_limit>-0.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment and geographic region as fixed effects and baseline HbA1c as a covariate.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c Over Time</title>
        <description>The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was assessed at Weeks 4, 8, 12, 16 and 20.
Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as fixed effects, and baseline HbA1c as a covariate.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, and 20.</time_frame>
        <population>The full analysis set where a baseline assessment and at least 1 valid postbaseline assessment were available. The analysis includes only data collected on or after baseline and within 7 days after the last dose of study medication or hyperglycemic rescue, whichever came first. Last observation carried forward was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Metformin 500 BID</title>
            <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Metformin 1000 BID</title>
            <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Alogliptin 12.5 BID + Metformin 500 BID</title>
            <description>Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Alogliptin 12.5 BID + Metformin 1000 BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c Over Time</title>
          <description>The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was assessed at Weeks 4, 8, 12, 16 and 20.
Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as fixed effects, and baseline HbA1c as a covariate.</description>
          <population>The full analysis set where a baseline assessment and at least 1 valid postbaseline assessment were available. The analysis includes only data collected on or after baseline and within 7 days after the last dose of study medication or hyperglycemic rescue, whichever came first. Last observation carried forward was utilized.</population>
          <units>percentage glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="111"/>
                <count group_id="O6" value="106"/>
                <count group_id="O7" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=95, 97, 89, 94, 102, 94, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.058"/>
                    <measurement group_id="O2" value="-0.34" spread="0.057"/>
                    <measurement group_id="O3" value="-0.42" spread="0.060"/>
                    <measurement group_id="O4" value="-0.37" spread="0.058"/>
                    <measurement group_id="O5" value="-0.58" spread="0.056"/>
                    <measurement group_id="O6" value="-0.70" spread="0.058"/>
                    <measurement group_id="O7" value="-0.75" spread="0.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=102, 104, 104, 103, 108, 102, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.073"/>
                    <measurement group_id="O2" value="-0.51" spread="0.073"/>
                    <measurement group_id="O3" value="-0.58" spread="0.072"/>
                    <measurement group_id="O4" value="-0.59" spread="0.073"/>
                    <measurement group_id="O5" value="-0.86" spread="0.071"/>
                    <measurement group_id="O6" value="-1.08" spread="0.073"/>
                    <measurement group_id="O7" value="-1.17" spread="0.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=102, 104, 104, 103, 108, 102, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.081"/>
                    <measurement group_id="O2" value="-0.53" spread="0.080"/>
                    <measurement group_id="O3" value="-0.62" spread="0.080"/>
                    <measurement group_id="O4" value="-0.68" spread="0.081"/>
                    <measurement group_id="O5" value="-1.02" spread="0.079"/>
                    <measurement group_id="O6" value="-1.22" spread="0.081"/>
                    <measurement group_id="O7" value="-1.40" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=102, 104, 104, 103, 108, 102, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.087"/>
                    <measurement group_id="O2" value="-0.58" spread="0.087"/>
                    <measurement group_id="O3" value="-0.63" spread="0.086"/>
                    <measurement group_id="O4" value="-0.72" spread="0.087"/>
                    <measurement group_id="O5" value="-1.09" spread="0.085"/>
                    <measurement group_id="O6" value="-1.26" spread="0.087"/>
                    <measurement group_id="O7" value="-1.50" spread="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=102, 104, 104, 103, 108, 102, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.092"/>
                    <measurement group_id="O2" value="-0.57" spread="0.091"/>
                    <measurement group_id="O3" value="-0.59" spread="0.091"/>
                    <measurement group_id="O4" value="-0.68" spread="0.092"/>
                    <measurement group_id="O5" value="-1.14" spread="0.089"/>
                    <measurement group_id="O6" value="-1.25" spread="0.092"/>
                    <measurement group_id="O7" value="-1.54" spread="0.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose Over Time</title>
        <description>The change from Baseline in fasting plasma glucose was assessed at Weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as fixed effects, and baseline fasting plasma glucose as a covariate.</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.</time_frame>
        <population>Full analysis set where a baseline assessment and at least 1 valid postbaseline assessment were available. Includes only data collected on or after baseline and within 1 day after the last dose of study medication or hyperglycemic rescue, whichever came first. Last observation carried forward was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Alogliptin 25 QD</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 12.5 BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Metformin 500 BID</title>
            <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Metformin 1000 BID</title>
            <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Alogliptin 12.5 BID + Metformin 500 BID</title>
            <description>Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Alogliptin 12.5 BID + Metformin 1000 BID</title>
            <description>Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose Over Time</title>
          <description>The change from Baseline in fasting plasma glucose was assessed at Weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as fixed effects, and baseline fasting plasma glucose as a covariate.</description>
          <population>Full analysis set where a baseline assessment and at least 1 valid postbaseline assessment were available. Includes only data collected on or after baseline and within 1 day after the last dose of study medication or hyperglycemic rescue, whichever came first. Last observation carried forward was utilized.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="111"/>
                <count group_id="O6" value="106"/>
                <count group_id="O7" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=102, 103, 94, 95, 104, 101, 109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="3.40"/>
                    <measurement group_id="O2" value="-3.9" spread="3.38"/>
                    <measurement group_id="O3" value="-11.9" spread="3.54"/>
                    <measurement group_id="O4" value="-12.6" spread="3.52"/>
                    <measurement group_id="O5" value="-23.1" spread="3.36"/>
                    <measurement group_id="O6" value="-32.7" spread="3.41"/>
                    <measurement group_id="O7" value="-36.3" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=105, 112, 105, 102, 108, 106, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="3.58"/>
                    <measurement group_id="O2" value="-7.4" spread="3.46"/>
                    <measurement group_id="O3" value="-11.6" spread="3.58"/>
                    <measurement group_id="O4" value="-14.5" spread="3.63"/>
                    <measurement group_id="O5" value="-22.2" spread="3.53"/>
                    <measurement group_id="O6" value="-34.5" spread="3.56"/>
                    <measurement group_id="O7" value="-43.6" spread="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=105, 112, 106, 106, 110, 106, 111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="3.69"/>
                    <measurement group_id="O2" value="-11.5" spread="3.57"/>
                    <measurement group_id="O3" value="-16.6" spread="3.67"/>
                    <measurement group_id="O4" value="-16.9" spread="3.67"/>
                    <measurement group_id="O5" value="-29.0" spread="3.60"/>
                    <measurement group_id="O6" value="-37.6" spread="3.67"/>
                    <measurement group_id="O7" value="-44.1" spread="3.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=105, 112, 106, 106, 110, 106, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="4.00"/>
                    <measurement group_id="O2" value="-10.9" spread="3.87"/>
                    <measurement group_id="O3" value="-12.1" spread="3.98"/>
                    <measurement group_id="O4" value="-11.8" spread="3.98"/>
                    <measurement group_id="O5" value="-30.7" spread="3.91"/>
                    <measurement group_id="O6" value="-32.9" spread="3.98"/>
                    <measurement group_id="O7" value="-43.8" spread="3.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=105, 112, 106, 106, 110, 106, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="4.16"/>
                    <measurement group_id="O2" value="-9.7" spread="4.03"/>
                    <measurement group_id="O3" value="-14.7" spread="4.14"/>
                    <measurement group_id="O4" value="-14.0" spread="4.14"/>
                    <measurement group_id="O5" value="-30.7" spread="4.06"/>
                    <measurement group_id="O6" value="-31.6" spread="4.14"/>
                    <measurement group_id="O7" value="-44.7" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=105, 112, 106, 106, 110, 106, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="4.17"/>
                    <measurement group_id="O2" value="-7.1" spread="4.04"/>
                    <measurement group_id="O3" value="-14.7" spread="4.15"/>
                    <measurement group_id="O4" value="-13.3" spread="4.15"/>
                    <measurement group_id="O5" value="-33.5" spread="4.07"/>
                    <measurement group_id="O6" value="-35.9" spread="4.15"/>
                    <measurement group_id="O7" value="-47.7" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=105, 112, 106, 106, 110, 106, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="4.36"/>
                    <measurement group_id="O2" value="-9.2" spread="4.22"/>
                    <measurement group_id="O3" value="-12.3" spread="4.34"/>
                    <measurement group_id="O4" value="-10.9" spread="4.34"/>
                    <measurement group_id="O5" value="-35.1" spread="4.25"/>
                    <measurement group_id="O6" value="-33.8" spread="4.34"/>
                    <measurement group_id="O7" value="-44.6" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=105, 112, 106, 106, 110, 106, 112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="4.52"/>
                    <measurement group_id="O2" value="-6.1" spread="4.37"/>
                    <measurement group_id="O3" value="-9.7" spread="4.49"/>
                    <measurement group_id="O4" value="-11.5" spread="4.49"/>
                    <measurement group_id="O5" value="-31.9" spread="4.41"/>
                    <measurement group_id="O6" value="-31.7" spread="4.49"/>
                    <measurement group_id="O7" value="-45.9" spread="4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events that occurred after the first dose of double-blind study medication and within 14 days after the last dose of double-blind study medication.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Alogliptin 25 QD</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Alogliptin 12.5 BID</title>
          <description>Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Metformin 500 BID</title>
          <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Metformin 1000 BID</title>
          <description>Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Alogliptin 12.5 BID + Metformin 500 BID</title>
          <description>Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Alogliptin 12.5 BID + Metformin 1000 BID</title>
          <description>Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Wandering pacemaker</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Multiple drug overdose intentional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Alveolitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="37" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. VP, Clinical Science</name_or_title>
      <organization>Takeda Global Research and Development Center, Inc.</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

